We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.27 | 0.83% | 32.92 | 32.92 | 32.94 | 32.99 | 32.44 | 32.56 | 2,221,577 | 19:07:00 |
From May 2023 to May 2024
By Adria Calatayud
Roche Holding said it received approval from the U.S. Food and Drug Administration for Vabysmo as treatment of macular edema following retinal vein occlusion, the drug's third indication.
The Swiss pharmaceutical giant said Friday that the approval was based on two late-stage studies that demonstrated early and sustained vision improvements.
Vabysmo is already approved for so-called "wet" age-related macular degeneration and diabetic macular edema, Roche said.
Write to Adria Calatayud at adria.calatayud@dowjones.com
(END) Dow Jones Newswires
October 27, 2023 01:25 ET (05:25 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
